N-(2-morpholinopyrimidin-4-yl)-3-[4-(trifluoromethyl)phenyl]isoxazol-5-amine

ID: ALA5093854

PubChem CID: 156368849

Max Phase: Preclinical

Molecular Formula: C18H16F3N5O2

Molecular Weight: 391.35

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1

Standard InChI:  InChI=1S/C18H16F3N5O2/c19-18(20,21)13-3-1-12(2-4-13)14-11-16(28-25-14)23-15-5-6-22-17(24-15)26-7-9-27-10-8-26/h1-6,11H,7-10H2,(H,22,23,24)

Standard InChI Key:  UHTZQLVQGDDTIF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 31  0  0  0  0  0  0  0  0999 V2000
    8.0790   -5.0497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.1330   -4.3624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4944   -3.2502    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6637   -3.2502    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.0251   -4.3624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1547   -4.6651    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.9817   -3.8381    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6793   -2.7083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5046   -1.8845    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6346   -2.1873    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.9380   -3.3108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.1163   -4.1421    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.0677   -3.6135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.8947   -2.7866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0243   -3.0893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3270   -4.2190    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.5001   -5.0459    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3704   -4.7432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0034   -4.6651    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7003   -5.7948    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5737   -6.0955    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7465   -5.2683    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0455   -4.1436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1728   -3.8346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6168   -5.5710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3141   -6.7007    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.7898   -4.7440    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.4871   -5.8737    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  5  1  2  0
  5  6  1  0
  6  7  1  0
  8  7  2  0
  9  8  1  0
 10  9  2  0
 11 10  1  0
 12 11  2  0
  7 12  1  0
 13 11  1  0
 13 14  1  0
 15 14  1  0
 16 15  1  0
 17 16  1  0
 18 17  1  0
 13 18  1  0
 19  2  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 23 22  1  0
 24 23  2  0
 19 24  1  0
 22 25  1  0
 25 26  1  0
 25 27  1  0
 25 28  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5093854

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 391.35

Molecular Weight (Monoisotopic): 391.1256

AlogP: 3.73

#Rotatable Bonds: 4

Polar Surface Area: 76.31

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.62

CX Basic pKa: 5.70

CX LogP: 4.02

CX LogD: 3.98

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.73

Np Likeness Score: -2.02

References

1.  (2021)  Isoxazole derivatives targeting tacc3 as anticancer agents, 

Source

Source(1):

• Patent Bioactivity Data